glp-1 egfr cut off receptor agonists' impact on cardio-renal outcomes and mortality in T2D with acute kidney disease GLP-1 receptor agonists are increasingly

Q: What should I do to prepare for the July 1 launch

With the exception of antiretroviral therapy, I cant think of another class of medications where there has been so much buzz, Dr Todd Brown of Johns Hopkins Medicine said during his plenary talk entitled GLP-1 Agonists: Are They a Cure for Everything? He concluded that the enthusiasm is warranted, but there are unanswered questions for people with HIV and global access will be a major challenge. Weight gain and metabolic abnormalities are a growing concern for people with HIV as they age

Unlike nausea, which typically fades with adaptation, constipation may require ongoing management

Treatment discontinuation due to side effects occurred in 4% of participants with both tirzepatide and placebo